{"id":"W2741746182","doi":"10.1016/j.hlc.2017.06.604","title":"Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data","year":2017,"lang":"en","type":"article","venue":"Heart Lung and Circulation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta","funders":"","keywords":"Alirocumab; PCSK9; Medicine; Evolocumab; Internal medicine; Acute coronary syndrome; Rosuvastatin; Statin; Interquartile range; Atorvastatin; Placebo; Gastroenterology; Apolipoprotein B; Myocardial infarction; Cholesterol; Lipoprotein; LDL receptor; Apolipoprotein A1; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001207924,0.0009200506,0.002253861,0.000167381,0.0003849577,0.001166017,0.0004522098,0.000801378,0.003397276],"category_scores_gemma":[0.001502696,0.0003537879,0.002309757,0.0001948025,0.0005727116,0.0008328271,0.0004918841,0.002183745,0.0003605072],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005958643,"about_ca_system_score_gemma":0.0008368718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001974714,"about_ca_topic_score_gemma":0.006386241,"domain_scores_codex":[0.9994361,0.0002507203,0.00004056633,0.00009002187,0.00005406288,0.0001286148],"domain_scores_gemma":[0.9992918,0.0001900381,0.0001600782,0.00007059664,0.00006101677,0.0002265183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9687547,0.00188276,0.005508895,0.0004947994,0.003319758,0.00003267759,0.00006211961,0.0002934134,0.001532555,0.0001376729,0.0009899354,0.01699068],"study_design_scores_gemma":[0.8212048,0.05665217,0.1065738,0.0002015551,0.008714086,0.000084735,0.0001599332,0.00143422,0.001446025,0.0007502458,0.002714366,0.00006401272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906747,0.004320737,0.0003274466,0.0006047178,0.0002588237,0.0002346487,0.001069527,0.00004035927,0.002469054],"genre_scores_gemma":[0.9940335,0.001574249,0.0003839493,0.0005839267,0.0002348083,0.0002498919,0.001026558,0.000008685186,0.001904331],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003397276,"threshold_uncertainty_score":0.01136506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09928528665819061,"score_gpt":0.3648585546714165,"score_spread":0.2655732680132259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}